ADVERTISEMENT
Log in here to read the desired article.
ADVERTISEMENT
This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 2071 entries already.
In parallel with the expansion of its collaboration with SK Bioscience Co. Ltd, the French pharmaceutical company Sanofi SA has announced Phase III testing of its licensed pneumococcal conjugate vaccine PCV21.
Screening a library of 712 market-approved drugs, German researchers have found that a cough medicine most efficiently reduced incurable lung fibrosis in mice and in vitro.
Novo Nordiks has licenced Photys Therapeutics PHICS platform to target a single cardiometabolic target. Photys got US$186m upfront.
Generative AI specialist DeepLife SAS has raises US$10m in a Series A financing led by YZR Capital and Relyens Innovation Santé with participation from Beiersdorf Venture Capital, Prunay Group, and existing investors.
Researchers at Sorbonne Paris have discovered that a membrane protein in adipocytes of obese mice and humans changes the lipid composition of adipose tissue macrophages rendering them more inflammatory and reducing insulin resistance.
Elevation Oncology Inc has inked a US$368m license agreement with Lonza subsidiary Synaffix BV under which Synaffix will link Elevation’s HER3 antibody seribantumab to a monomethyl auristatin E (MMAE) toxic payload with broad therapeutic index.
RNA editing specialist ProQR Therapeutics NV has deepened its collaboration with the Rett Syndrome Research Trust, which extented its funding of the preclinical MECP2 inhibitor AX-2402 to US$9.1m to speed up the translation to clinical trials.
Swiss Noema Pharma AG has cashed in a CHF27m extention to its Series B financing that is used to advance four Phase II programmes in neurology.
Dutch inflammation specialist Citryll BV has raised €85m to push clininal testing of its lead candidate, CIT-013, a bifunctional antibody that prevents the release of neutrophil extracellular traps (NETs) from neutrophil granulocytes into the cytoplasm, thus blocking inflammatory and autoimmune diseases at its very roots.
The British NICE has defined the conditions for the reimbursement of Eli Lilly’s obesity blockbuster tirzepatide. This makes the UK the first country in which patients do not have to pay for the drug out of their own pocket.